Through the integration of Hoechst Marion Roussel and Rhone-Poulenc Rorer, Aventis is creating a truly global, inexorably interlocked network of drug discovery and development capabilities. The need to improve sales performance and increase capitalization--a defense against takeover--drove the merger. But the merger also gave it both more R&D resources and an opportunity to retool its process. As this question and answer session with Aventis's Frank Douglas, head of R&D, notes, the company is emphasizing the creation of capabilities through internal and external investments, rather than scale. The reconfiguration draws on Douglas's experience in HMR's previous, and far less successful mergers. Aventis has set clear project priorities and created interlocking R&D functions in the US, France, and Germany, with platform technology resources-wherever they're located-directed to priority projects. The result, Douglas believes, is a system that focuses on optimizing the global portfolio, not the site portfolio. The company's challenge now, and perhaps its biggest opportunity, comes from being a truly multinational organization. Aventis has core drug discovery and development sites in the US, France, and Germany, and has chosen to distribute decision-making equally among them. That facilitates outreach to academia and biotechs, but it's not the most efficient way to organize and requires extra time and work for communication.
by Mark L. Ratner
Among the never-ending consolidations in the pharmaceutical industry, Aventis SA —formed a year ago through the merger of Hoechst...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
